Biologic Disease-modifying Antirheumatic Drug (bDMARD)-induced Neutropenia: A Registry from a Retrospective Cohort of Patients with Rheumatic Diseases Treated with 3 Classes of Intravenous bDMARD.
Identifieur interne : 001891 ( Main/Exploration ); précédent : 001890; suivant : 001892Biologic Disease-modifying Antirheumatic Drug (bDMARD)-induced Neutropenia: A Registry from a Retrospective Cohort of Patients with Rheumatic Diseases Treated with 3 Classes of Intravenous bDMARD.
Auteurs : Francisco Espinoza [Chili] ; Pierre Le Blay [Chili] ; Bernard Combe [Chili]Source :
- The Journal of rheumatology [ 0315-162X ] ; 2017.
Descripteurs français
- KwdFr :
- Abatacept (effets indésirables), Abatacept (usage thérapeutique), Adulte, Adulte d'âge moyen, Anticorps monoclonaux humanisés (effets indésirables), Anticorps monoclonaux humanisés (usage thérapeutique), Antirhumatismaux (effets indésirables), Antirhumatismaux (usage thérapeutique), Enregistrements, Femelle, Humains, Infliximab (effets indésirables), Infliximab (usage thérapeutique), Mâle, Méthotrexate (effets indésirables), Méthotrexate (usage thérapeutique), Neutropénie (), Produits biologiques (effets indésirables), Produits biologiques (usage thérapeutique), Rhumatismes (traitement médicamenteux), Sujet âgé, Sujet âgé de 80 ans ou plus, Études rétrospectives.
- MESH :
- effets indésirables : Abatacept, Anticorps monoclonaux humanisés, Antirhumatismaux, Infliximab, Méthotrexate, Produits biologiques.
- traitement médicamenteux : Rhumatismes.
- usage thérapeutique : Abatacept, Anticorps monoclonaux humanisés, Antirhumatismaux, Infliximab, Méthotrexate, Produits biologiques.
- Adulte, Adulte d'âge moyen, Enregistrements, Femelle, Humains, Mâle, Neutropénie, Sujet âgé, Sujet âgé de 80 ans ou plus, Études rétrospectives.
English descriptors
- KwdEn :
- Abatacept (adverse effects), Abatacept (therapeutic use), Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized (adverse effects), Antibodies, Monoclonal, Humanized (therapeutic use), Antirheumatic Agents (adverse effects), Antirheumatic Agents (therapeutic use), Biological Products (adverse effects), Biological Products (therapeutic use), Female, Humans, Infliximab (adverse effects), Infliximab (therapeutic use), Male, Methotrexate (adverse effects), Methotrexate (therapeutic use), Middle Aged, Neutropenia (chemically induced), Registries, Retrospective Studies, Rheumatic Diseases (drug therapy).
- MESH :
- chemical , adverse effects : Abatacept, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Biological Products, Infliximab, Methotrexate.
- chemical , therapeutic use : Abatacept, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Biological Products, Infliximab, Methotrexate.
- chemically induced : Neutropenia.
- drug therapy : Rheumatic Diseases.
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Registries, Retrospective Studies.
- mix :
Abstract
To examine the rate, risks factors, and consequences of neutropenia induced by intravenous (IV) biologic disease-modifying antirheumatic drugs (bDMARD).
Url:
DOI: 10.3899/jrheum.150457
PubMed: 28412711
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000B67
- to stream PubMed, to step Curation: 000B67
- to stream PubMed, to step Checkpoint: 000C20
- to stream Ncbi, to step Merge: 001552
- to stream Ncbi, to step Curation: 001552
- to stream Ncbi, to step Checkpoint: 001552
- to stream Hal, to step Corpus: 000008
- to stream Hal, to step Curation: 000008
- to stream Hal, to step Checkpoint: 000042
- to stream Main, to step Merge: 001890
- to stream Main, to step Curation: 001891
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Biologic Disease-modifying Antirheumatic Drug (bDMARD)-induced Neutropenia: A Registry from a Retrospective Cohort of Patients with Rheumatic Diseases Treated with 3 Classes of Intravenous bDMARD.</title><author><name sortKey="Espinoza, Francisco" sort="Espinoza, Francisco" uniqKey="Espinoza F" first="Francisco" last="Espinoza">Francisco Espinoza</name><affiliation wicri:level="1"><nlm:affiliation>From the Department of Rheumatology, Lapeyronie University Hospital, University of Montpellier, Montpellier, France; Department of Rheumatology, School of Medicine, Universidad de los Andes, Santiago, Chile. fespinoza@uandes.cl.</nlm:affiliation><country xml:lang="fr">Chili</country><wicri:regionArea>From the Department of Rheumatology, Lapeyronie University Hospital, University of Montpellier, Montpellier, France; Department of Rheumatology, School of Medicine, Universidad de los Andes, Santiago</wicri:regionArea><wicri:noRegion>Santiago</wicri:noRegion></affiliation></author><author><name sortKey="Le Blay, Pierre" sort="Le Blay, Pierre" uniqKey="Le Blay P" first="Pierre" last="Le Blay">Pierre Le Blay</name><affiliation wicri:level="1"><nlm:affiliation>From the Department of Rheumatology, Lapeyronie University Hospital, University of Montpellier, Montpellier, France; Department of Rheumatology, School of Medicine, Universidad de los Andes, Santiago, Chile.</nlm:affiliation><country xml:lang="fr">Chili</country><wicri:regionArea>From the Department of Rheumatology, Lapeyronie University Hospital, University of Montpellier, Montpellier, France; Department of Rheumatology, School of Medicine, Universidad de los Andes, Santiago</wicri:regionArea><wicri:noRegion>Santiago</wicri:noRegion></affiliation></author><author><name sortKey="Combe, Bernard" sort="Combe, Bernard" uniqKey="Combe B" first="Bernard" last="Combe">Bernard Combe</name><affiliation wicri:level="1"><nlm:affiliation>From the Department of Rheumatology, Lapeyronie University Hospital, University of Montpellier, Montpellier, France; Department of Rheumatology, School of Medicine, Universidad de los Andes, Santiago, Chile.</nlm:affiliation><country xml:lang="fr">Chili</country><wicri:regionArea>From the Department of Rheumatology, Lapeyronie University Hospital, University of Montpellier, Montpellier, France; Department of Rheumatology, School of Medicine, Universidad de los Andes, Santiago</wicri:regionArea><wicri:noRegion>Santiago</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28412711</idno><idno type="pmid">28412711</idno><idno type="doi">10.3899/jrheum.150457</idno><idno type="wicri:Area/PubMed/Corpus">000B67</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B67</idno><idno type="wicri:Area/PubMed/Curation">000B67</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B67</idno><idno type="wicri:Area/PubMed/Checkpoint">000C20</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000C20</idno><idno type="wicri:Area/Ncbi/Merge">001552</idno><idno type="wicri:Area/Ncbi/Curation">001552</idno><idno type="wicri:Area/Ncbi/Checkpoint">001552</idno><idno type="wicri:doubleKey">0315-162X:2017:Espinoza F:biologic:disease:modifying</idno><idno type="wicri:source">HAL</idno><idno type="RBID">Hal:hal-01762808</idno><idno type="url">https://hal.archives-ouvertes.fr/hal-01762808</idno><idno type="wicri:Area/Hal/Corpus">000008</idno><idno type="wicri:Area/Hal/Curation">000008</idno><idno type="wicri:Area/Hal/Checkpoint">000042</idno><idno type="wicri:explorRef" wicri:stream="Hal" wicri:step="Checkpoint">000042</idno><idno type="wicri:doubleKey">0315-162X:2017:Espinoza F:biologic:disease:modifying</idno><idno type="wicri:Area/Main/Merge">001890</idno><idno type="wicri:Area/Main/Curation">001891</idno><idno type="wicri:Area/Main/Exploration">001891</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Biologic Disease-modifying Antirheumatic Drug (bDMARD)-induced Neutropenia: A Registry from a Retrospective Cohort of Patients with Rheumatic Diseases Treated with 3 Classes of Intravenous bDMARD.</title><author><name sortKey="Espinoza, Francisco" sort="Espinoza, Francisco" uniqKey="Espinoza F" first="Francisco" last="Espinoza">Francisco Espinoza</name><affiliation wicri:level="1"><nlm:affiliation>From the Department of Rheumatology, Lapeyronie University Hospital, University of Montpellier, Montpellier, France; Department of Rheumatology, School of Medicine, Universidad de los Andes, Santiago, Chile. fespinoza@uandes.cl.</nlm:affiliation><country xml:lang="fr">Chili</country><wicri:regionArea>From the Department of Rheumatology, Lapeyronie University Hospital, University of Montpellier, Montpellier, France; Department of Rheumatology, School of Medicine, Universidad de los Andes, Santiago</wicri:regionArea><wicri:noRegion>Santiago</wicri:noRegion></affiliation></author><author><name sortKey="Le Blay, Pierre" sort="Le Blay, Pierre" uniqKey="Le Blay P" first="Pierre" last="Le Blay">Pierre Le Blay</name><affiliation wicri:level="1"><nlm:affiliation>From the Department of Rheumatology, Lapeyronie University Hospital, University of Montpellier, Montpellier, France; Department of Rheumatology, School of Medicine, Universidad de los Andes, Santiago, Chile.</nlm:affiliation><country xml:lang="fr">Chili</country><wicri:regionArea>From the Department of Rheumatology, Lapeyronie University Hospital, University of Montpellier, Montpellier, France; Department of Rheumatology, School of Medicine, Universidad de los Andes, Santiago</wicri:regionArea><wicri:noRegion>Santiago</wicri:noRegion></affiliation></author><author><name sortKey="Combe, Bernard" sort="Combe, Bernard" uniqKey="Combe B" first="Bernard" last="Combe">Bernard Combe</name><affiliation wicri:level="1"><nlm:affiliation>From the Department of Rheumatology, Lapeyronie University Hospital, University of Montpellier, Montpellier, France; Department of Rheumatology, School of Medicine, Universidad de los Andes, Santiago, Chile.</nlm:affiliation><country xml:lang="fr">Chili</country><wicri:regionArea>From the Department of Rheumatology, Lapeyronie University Hospital, University of Montpellier, Montpellier, France; Department of Rheumatology, School of Medicine, Universidad de los Andes, Santiago</wicri:regionArea><wicri:noRegion>Santiago</wicri:noRegion></affiliation></author></analytic><series><title level="j">The Journal of rheumatology</title><idno type="ISSN">0315-162X</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abatacept (adverse effects)</term><term>Abatacept (therapeutic use)</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antibodies, Monoclonal, Humanized (adverse effects)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Antirheumatic Agents (adverse effects)</term><term>Antirheumatic Agents (therapeutic use)</term><term>Biological Products (adverse effects)</term><term>Biological Products (therapeutic use)</term><term>Female</term><term>Humans</term><term>Infliximab (adverse effects)</term><term>Infliximab (therapeutic use)</term><term>Male</term><term>Methotrexate (adverse effects)</term><term>Methotrexate (therapeutic use)</term><term>Middle Aged</term><term>Neutropenia (chemically induced)</term><term>Registries</term><term>Retrospective Studies</term><term>Rheumatic Diseases (drug therapy)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Abatacept (effets indésirables)</term><term>Abatacept (usage thérapeutique)</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux humanisés (effets indésirables)</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Antirhumatismaux (effets indésirables)</term><term>Antirhumatismaux (usage thérapeutique)</term><term>Enregistrements</term><term>Femelle</term><term>Humains</term><term>Infliximab (effets indésirables)</term><term>Infliximab (usage thérapeutique)</term><term>Mâle</term><term>Méthotrexate (effets indésirables)</term><term>Méthotrexate (usage thérapeutique)</term><term>Neutropénie ()</term><term>Produits biologiques (effets indésirables)</term><term>Produits biologiques (usage thérapeutique)</term><term>Rhumatismes (traitement médicamenteux)</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Abatacept</term><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term><term>Biological Products</term><term>Infliximab</term><term>Methotrexate</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Abatacept</term><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term><term>Biological Products</term><term>Infliximab</term><term>Methotrexate</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Neutropenia</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Rheumatic Diseases</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Abatacept</term><term>Anticorps monoclonaux humanisés</term><term>Antirhumatismaux</term><term>Infliximab</term><term>Méthotrexate</term><term>Produits biologiques</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Rhumatismes</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Abatacept</term><term>Anticorps monoclonaux humanisés</term><term>Antirhumatismaux</term><term>Infliximab</term><term>Méthotrexate</term><term>Produits biologiques</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Registries</term><term>Retrospective Studies</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Enregistrements</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Neutropénie</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Études rétrospectives</term></keywords><keywords scheme="mix" xml:lang="en"><term>ANTIRHEUMATIC AGENTS</term><term>INFECTION</term><term>NEUTROPENIA</term><term>TOCILIZUMAB</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To examine the rate, risks factors, and consequences of neutropenia induced by intravenous (IV) biologic disease-modifying antirheumatic drugs (bDMARD).</div></front></TEI><affiliations><list><country><li>Chili</li></country></list><tree><country name="Chili"><noRegion><name sortKey="Espinoza, Francisco" sort="Espinoza, Francisco" uniqKey="Espinoza F" first="Francisco" last="Espinoza">Francisco Espinoza</name></noRegion><name sortKey="Combe, Bernard" sort="Combe, Bernard" uniqKey="Combe B" first="Bernard" last="Combe">Bernard Combe</name><name sortKey="Le Blay, Pierre" sort="Le Blay, Pierre" uniqKey="Le Blay P" first="Pierre" last="Le Blay">Pierre Le Blay</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001891 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001891 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28412711
|texte= Biologic Disease-modifying Antirheumatic Drug (bDMARD)-induced Neutropenia: A Registry from a Retrospective Cohort of Patients with Rheumatic Diseases Treated with 3 Classes of Intravenous bDMARD.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28412711" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |